Send this resource to your team or professional network.
Melanotan 2 Canada research examines a synthetic melanocortin agonist (MT-II) developed at the University of Arizona, studied for its effects on skin pigmentation and appetite. For primary sources, see Hadley et al. original MT-II synthesis (PubMed) and Wessells et al. on melanocortin effects (PubMed).
Melanotan 2 Canada: Mechanism and Research Evidence
Melanotan II (MT-II, also written Melanotan 2) is a synthetic melanocortin agonist investigated in pigmentation and central-signalling research. This guide separates receptor biology, small human studies, adverse-event reports and Canadian regulatory guidance.
Canadian status: Health Canada includes Melanotan I and II in its advisory about unauthorized injectable peptide drugs. Research-use-only wording does not confer authorization or exempt a product from regulatory requirements. Read the April 2026 advisory.
Key Takeaways
- Melanotan II (MT-II) is a synthetic cyclic analogue of alpha-melanocyte-stimulating hormone (a-MSH) and a non-selective melanocortin receptor agonist.
- It acts on MC1R (linked to melanogenesis) and MC3R/MC4R (linked in research to sexual-function and appetite pathways).
- The FDA-approved peptide bremelanotide (PT-141/Vyleesi) is chemically related to MT-II and emerged from the same melanocortin research programme.
- Published literature documents real concerns: nausea, spontaneous erections, darkening and eruption of melanocytic naevi, and case reports linking use to melanoma.
- Health Canada has warned that unauthorised melanotan and other injectable peptide products are not approved and may pose serious risks; RUO material is for research only.
What Is Melanotan II?
Melanotan II is a synthetic, cyclic lactam heptapeptide modelled on the endogenous hormone a-MSH. It was first synthesised at the University of Arizona in the late 1980s and early 1990s by a team including Victor Hruby and Mac Hadley, who set out to design a superpotent a-MSH analogue that could induce protective skin pigmentation without ultraviolet exposure.
The original research hypothesis was preventive: could a stable melanocortin agonist trigger melanogenesis and reduce skin-cancer risk in high-UV-risk populations? To achieve this, the researchers cyclised the peptide with a lactam bridge, which dramatically increased its enzymatic stability, receptor affinity and plasma half-life compared with native a-MSH. If you are new to this class of molecules, our primer on What are peptides? provides useful background.
Because MT-II is a broad, non-selective agonist rather than a receptor-specific one, it became a valuable pharmacological tool for probing the entire melanocortin system in preclinical settings. That same lack of selectivity, however, is why it produces such a wide range of effects and why its safety profile is complicated.
How Melanotan II Works (Mechanism)
MT-II activates several melanocortin receptor subtypes, including MC1R, MC3R, MC4R and MC5R. These receptors participate in different pathways, so an observation in one experimental system cannot describe every effect of the compound.
MC1R and the pigmentation pathway. MC1R sits on melanocytes. When Melanotan II binds it, it stimulates melanogenesis, driving production of eumelanin, the darker photoprotective pigment. In the foundational human pilot study, this produced UV-independent skin darkening in test subjects.
MC3R and MC4R and the central pathway. MC4R (and to a lesser extent MC3R) are concentrated in the hypothalamus and central nervous system, where the melanocortin system helps regulate sexual arousal and appetite. Activation of these receptors is thought to underlie the pro-erectile and appetite-suppressing signals observed with MT-II in research. Knockout studies with related melanocortin agonists confirm that the sexual-behaviour effect depends on functional MC4R.
This dual footprint – MC1R for tanning and MC4R for central sexual-function signalling – explains why a peptide first developed for photoprotection unexpectedly became the starting point for erectile-function research and, ultimately, the FDA-approved drug bremelanotide.
Melanotan II at a Glance
| Property | Detail |
|---|---|
| Compound class | Synthetic cyclic heptapeptide; a-MSH analogue |
| Receptor targets | Non-selective melanocortin agonist (MC1R, MC3R, MC4R, MC5R) |
| Studied for (research) | Melanogenesis/photoprotection; melanocortin-mediated sexual-function pathways; appetite signalling |
| Related compound | Bremelanotide (PT-141 / Vyleesi), an FDA-approved melanocortin agonist |
| Format | Lyophilised powder for laboratory reconstitution |
| Regulatory status | Research Use Only; not approved by Health Canada; not for human use |
Melanotan II Research Applications
Much of the cited literature examines pigmentation biology and melanocortin-mediated sexual-function pathways. Appetite and energy-balance signalling form a related research area.
Pigmentation and photoprotection research. Because MC1R activation drives eumelanin synthesis, MT-II has been used to explore UV-independent tanning and the broader biology of melanogenesis. This was the compound’s original purpose, framed as a possible strategy to reduce UV-related skin damage in preclinical models. It is closely related to afamelanotide (Melanotan I), a more MC1R-selective analogue that later reached regulatory approval for a rare photosensitivity disorder. That approval does not apply to Melanotan II.
Sexual-function research via the melanocortin pathway. The discovery of spontaneous erections during early tanning studies redirected part of the research programme toward the central melanocortin system and erectile physiology. This line of work informs the wider field of sexual health research peptides and ultimately contributed to the development of bremelanotide. Appetite and energy-balance signalling through MC3R/MC4R is a third, less prominent research avenue.
Key Research & Evidence
The evidence includes early controlled human pharmacology and later adverse-event reports. These study types answer different questions: small trials can measure selected responses, while case reports identify possible harms without establishing incidence or causation.
Dorr and colleagues (1996) conducted a placebo-controlled pilot study in three male volunteers. Two developed increased pigmentation. Reported effects included nausea, fatigue or somnolence, yawning and spontaneous erections. The sample was too small to establish long-term safety or a general benefit-risk profile.
The sexual-function signal was then studied directly. Wessells and colleagues ran a double-blind, placebo-controlled crossover study in men with psychogenic erectile dysfunction, reporting clinically apparent erections in 8 of 10 participants on MT-II versus none on placebo (Wessells et al., 1998, J Urol). For mechanism, a peer-reviewed review of melanocortin receptors, melanotropic peptides and penile erection consolidates how MC4R signalling links these peptides to erectile physiology (King et al., melanocortin receptors and penile erection).
On the safety side, dermatology journals provide the most sobering data. A widely cited report described eruptive naevi and darkening of pre-existing naevi just 24 hours after a single injection of Melanotan II (Eruptive naevi after melanotan II), while the British Journal of Dermatology documented eruptive melanocytic naevi following melanotan injection (Eruptive melanocytic naevi following melanotan injection, BJD).
A comprehensive review by Brennan and colleagues catalogued eighteen clinical trials and twenty-one case presentations, noting nausea, darkening of naevi, yawning, systemic toxicity and melanoma among reported outcomes (Brennan et al., 2014). More recent literature continues to flag risk, including a 2025 report examining Melanotan II nasal spray as a possible factor in oral mucosal melanoma (Melanotan II and oral mucosal melanoma, 2025).
Safety & Research Considerations
Read safety findings alongside the study design, exposure information and product-quality limitations. A research label does not resolve the risks described below.
Acute effects. The most consistently reported acute effects across studies are nausea, facial flushing, a stretching-and-yawning complex, and spontaneous, sometimes prolonged, erections. These were dose-limiting even in controlled early human pharmacology work.
Melanocytic and melanoma concerns. The dermatology literature repeatedly documents darkening of existing moles, eruption of new naevi and atypical (dysplastic) naevi in melanotan users. Several case reports describe melanoma arising in or near changing moles during or after use. Because MT-II stimulates melanocytes directly through MC1R, the theoretical and observed concern that it may drive proliferation or obscure early melanoma warning signs is taken seriously by clinicians.
Product-quality concerns. Unverified identity, content, sterility and storage conditions make reports involving online products difficult to interpret. A result from a controlled study does not validate an unrelated commercial preparation.
Case reports are signals for further investigation. They cannot by themselves prove that MT-II caused melanoma or quantify the risk, and the absence of definitive causation does not establish safety.
What People Online Are Saying About Melanotan II
Community and forum discussion is worth reviewing as anecdotal sentiment, not evidence. A qualitative academic study of online discussion forums found users openly trading tips on reconstitution and reporting rapid, dramatic tanning, alongside frank descriptions of nausea and other unwanted effects (Melanotan II user experience, Dermatology (Karger)).
Public reporting echoes this split sentiment: long-term users describe pronounced pigmentation results, while dermatologists and public-health researchers highlight the unregulated supply and mole-change risks. Recent dermatology papers specifically examine how social media promotes unregulated melanotan use and the emerging public-health concerns that follow.
The recurring theme across anecdotal sources is a trade-off users acknowledge themselves: visible cosmetic results versus real, discussed risks around nausea, mole changes and unknown product quality. For research audiences, that sentiment is a reminder of why controlled, RUO handling and honest safety framing matter.
How to Evaluate Research Material and Documentation
For a laboratory procurement decision, confirm the exact material, supplier identity, lot number and analytical methods. Review identity, chromatographic purity and measured content separately. A purity percentage alone does not establish sterility, stability or suitability for human use.
The Melanotan II research product page provides the listed vial information. Match any available report in the Certificate of Analysis directory to the supplied lot and request missing measurements required by your protocol. Laboratory documentation and regulatory authorization are separate matters.
For handling background, use the peptide storage guide. Follow the material documentation and institutional procedures rather than general internet preparation instructions.
Frequently Asked Questions
Is Melanotan II approved in Canada?
Health Canada lists Melanotan I and II among unauthorized injectable peptide drugs in its April 2026 advisory. A research-use-only label does not confer authorization or exempt a product from regulatory requirements.
What is the difference between Melanotan I and Melanotan II?
They are different alpha-MSH analogues. Melanotan II is a cyclic heptapeptide with activity at several melanocortin receptor subtypes. Evidence for one molecule or a finished prescription formulation cannot be transferred to the other.
How is Melanotan II related to PT-141?
Bremelanotide, also called PT-141, is a related but distinct melanocortin agonist. The prescription product Vyleesi contains bremelanotide; it is not Melanotan II, and a research vial is not equivalent to that medicine.
Do melanoma case reports prove that Melanotan II causes cancer?
No. Case reports describe events and raise possible safety signals, but they cannot by themselves establish causation or quantify risk. Reported mole changes and melanoma cases warrant concern; uncertainty is not evidence of safety.
What should a laboratory check on a Melanotan II COA?
Match the compound and lot, then review the laboratory, test date, methods and results for identity, purity and content. Purity alone does not establish sterility, stability, safety or regulatory authorization.
Is Melanotan II safe for human use?
Human safety has not been established by the small studies and case reports reviewed here. Health Canada advises consumers not to buy or use unauthorized peptide drugs. This guide gives no instructions for human use.
Scope of This Guide
This article explains published research and its limitations. It provides no dosing, administration or treatment advice. Anglo catalogue materials are offered for laboratory research, not human or veterinary administration. A product listing, analytical report or research-use label does not establish drug authorization. Contact a healthcare professional if you have used an unauthorized product and have health concerns.
References
- Dorr RT, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-84. PMID 8637402. View study
- Wessells H, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo-controlled crossover study. J Urol. 1998;160(2):389-393. View study
- King SH, et al. Melanocortin receptors, melanotropic peptides and penile erection. PMC2694735. View study
- Brennan R, Wells JSG, Van Hout MC. An unhealthy glow? A review of melanotan use and associated clinical outcomes. Perform Enhanc Health. 2014. View study
- Eruptive naevi and darkening of pre-existing naevi 24 h after a single injection of melanotan II. PMID 24334249. View study
- Eruptive melanocytic naevi following melanotan injection. Br J Dermatol. 2009;161(3):707. View study
- Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma. 2025. PMID 40210573. View study
- Melanotan II user experience: a qualitative study of online discussion forums. Dermatology (Karger). 2021;237(6):995. View study
- Health Canada. Public advisory: think twice before injecting peptides bought online (includes melanotan I and II). View source
- DermNet NZ. Melanotan II overview and clinical concerns. View source
Related Peptide Research Articles
Related articles: Are Peptides Legal in Canada?, What Are Peptides?, GHK-Cu vs BPC-157.
